SPTB

Across TCGA pan-cancer cohorts, SPTB mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SPTB data layer compared with 22 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher SPTB mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SPTB expression acts as an unfavorable survival marker, although some lineages such as CCRCC and COAD show a favorable association.

CCRCC, PDAC, and LUAD are the cancer types where SPTB mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.921	0.692	<.001	31	view →
PDAC	OS	Median	III,IV	0.537	1.000	.008	16	view →
LUAD	DFS	Tertile	III,IV	0.360	0.920	.013	12	view →
COAD	DFS	Tertile	III,IV	1.000	0.808	.049	6	view →
HNSC	DFS	Median	III,IV	1.000	0.939	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SPTB–CCRCC (DFS)

Open the CCRCC breakdown →